Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Sara Belli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland. Hauptthemen laut MEDLINE: Macaca fascicularis, Neoplasms, T-Lymphocytes, Regulatory, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
The multifaceted IL‐2/IL‐2R biology and its modulation by promising therapeutic agents are highly relevant topics in the cancer immunotherapy field. A novel CD25‐Treg‐depleting antibody (Vopikitug, RG6292) has been engineered to preserve IL‐2 signaling on effector T cells to enhance effector activation and antitumor immunity, and is currently being evaluated in the clinic. The Entry into Human‐enabling framework described here investigated the characteristics of RG6292, from in vitro quantification of CD25 and RG6292 pharmacology using human tissues to in vivo assessment of PK/PD/safety relationships in cynomolgus monkeys as non‐human primate species (NHP). Fundamental knowledge on CD25 and Treg biology in healthy and diseased tissues across NHP and human highlighted the commonalities between these species in regard to the target biology and demonstrated the conservation of RG6292 properties between NHP and human. The integration of in vitro and in vivo PK/PD/safety data from these species enabled the identification of human relevant safety risks, the selection of the most appropriate safe starting dose and the projection of the pharmacologically‐relevant dose range. The first clinical data obtained for RG6292 in patients verified the appropriateness of the described approaches as well as validated the full clinical relevance of the projected safety, PK, and PD profiles from animal to man. This work shows how the integration of mechanistic non‐clinical data increases the predictive value for human, allowing efficient transition of drug candidates and optimizations of early clinical investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roche Innovation Center Basel, Roche Pharmaceutical Research and Development (pRED), Basel, Switzerland.
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Development (pRED), Penzberg, Germany.
ORCID-Profile: Sara Belli, Maria Amann, Lucy Hutchinson, Laurène Pousse, Afsaneh Abdolzade-Bavil, Bjoern Jacobsen, Gabriel Schnetzler, Christophe Boetsch, Estelle Marrer-Berger
Zitieren
APA
Belli, S., Amann, M., Hutchinson, L., Pousse, L., Abdolzade-Bavil, A., Justies, N., Jacobsen, B., Ploix, C., Tselempi, E., Tosevski, V., Koll, H., Schnetzler, G., Boetsch, C., & Marrer-Berger, E. (2024). Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3303
Vancouver
Belli S, Amann M, Hutchinson L, Pousse L, Abdolzade-Bavil A, Justies N, et al. Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3303
BibTeX
@article{Belli2024,
author = {Belli, Sara and Amann, Maria and Hutchinson, Lucy and Pousse, Laurène and Abdolzade-Bavil, Afsaneh and Justies, Nicole and Jacobsen, Bjoern and Ploix, Corinne and Tselempi, Eleni and Tosevski, Vinko and Koll, Hans and Schnetzler, Gabriel and Boetsch, Christophe and Marrer-Berger, Estelle},
title = {Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3303}
}
EUVIMED